NovaBridge Biosciences Pursues Hong Kong Listing Amid Strategic Shift

I-MAB ( (IMAB) ) has shared an update.

NovaBridge Biosciences has filed an application for a dual primary listing on the Hong Kong Stock Exchange, alongside an initial public offering of its ordinary shares. This move is part of a broader strategy to adopt a new business model, aiming to advance therapeutic assets through strategic partnerships and specialized subsidiaries. On October 14, 2025, the company entered into a Series A Preferred Stock Subscription Agreement with Visara, one of its subsidiaries. The company also completed a safety assessment for a Phase 1b clinical trial of givastomig in May 2025, with further data expected in early 2026.

The most recent analyst rating on (IMAB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.

Spark’s Take on IMAB Stock

According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.

The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.

To see Spark’s full report on IMAB stock, click here.

More about I-MAB

NovaBridge Biosciences operates in the biotechnology industry, focusing on developing high-value therapeutic assets. The company is transitioning to a biotechnology platform model, establishing specialized subsidiaries to enhance oversight and operational focus.

Average Trading Volume: 2,740,570

Technical Sentiment Signal: Buy

Current Market Cap: $360.3M

For detailed information about IMAB stock, go to TipRanks’ Stock Analysis page.